S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
S&P 500   5,249.49 (+0.02%)
DOW   39,753.43 (-0.02%)
QQQ   444.26 (-0.13%)
AAPL   171.28 (-1.17%)
MSFT   420.11 (-0.31%)
META   485.84 (-1.62%)
GOOGL   150.77 (-0.07%)
AMZN   180.11 (+0.16%)
TSLA   177.57 (-1.26%)
NVDA   906.73 (+0.47%)
NIO   4.57 (-2.14%)
AMD   180.65 (+0.59%)
BABA   72.45 (+1.20%)
T   17.64 (+0.51%)
F   13.17 (+0.84%)
MU   117.93 (-1.02%)
CGC   9.77 (+2.30%)
GE   175.17 (-2.75%)
DIS   122.63 (+1.36%)
AMC   3.68 (-15.21%)
PFE   28.00 (+0.79%)
PYPL   67.18 (+0.92%)
XOM   115.86 (+0.77%)
NASDAQ:PYPD

PolyPid (PYPD) Stock Price, News & Analysis

$4.60
-0.10 (-2.13%)
(As of 10:16 AM ET)
Today's Range
$4.60
$5.50
50-Day Range
$4.64
$6.99
52-Week Range
$3.57
$14.70
Volume
4,515 shs
Average Volume
7,488 shs
Market Capitalization
$22.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
PYPD stock logo

About PolyPid Stock (NASDAQ:PYPD)

PolyPid Ltd., a clinical-stage pharmaceutical company, develops, manufactures, and commercializes products based on polymer-lipid encapsulation matrix (PLEX) platform to address unmet medical needs. Its lead product candidate is D-PLEX100, which helps in the prevention of sternal (bone) surgical site infections (SSIs), as well as for the prevention of abdominal (soft tissue) SSIs. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.

PYPD Stock Price History

PYPD Stock News Headlines

Trending Stocks Sent To You In Real Time
Sign up today and get instant access to our next stock alert! You do not want to miss out on this next pick! Our stock picks have been known to soar!
Urgent: Protect Your Investments from a Chinese Invasion
An alarming new reality is unfolding across America. The United States is bracing for the unthinkable - a potential Chinese invasion.
PolyPid Ltd. (PYPD)
PolyPid's Earnings: A Preview
See More Headlines
Receive PYPD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PolyPid and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/14/2024
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:PYPD
Fax
N/A
Employees
57
Year Founded
N/A

Profitability

Net Income
$-23,860,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($1.27) per share

Miscellaneous

Free Float
3,612,000
Market Cap
$22.08 million
Optionable
Optionable
Beta
1.43
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

  • Ms. Dikla Czaczkes Akselbrad (Age 51)
    CEO & Director
    Comp: $422.33k
  • Ms. Dalit Hazan (Age 53)
    Executive Vice President of R&D and Clinical & Regulatory Affairs
    Comp: $312.25k
  • Mr. Ori Warshavsky (Age 46)
    Chief Operating Officer - US
    Comp: $335.52k
  • Mr. Jonny Missulawin (Age 37)
    Chief Financial Officer
  • Ms. Maria Rubin
    Vice President of Operations
  • Mr. Tal Vilnai
    General Counsel & Corporate Secretary
  • Ms. Rivi Lev-ari
    Vice President of Human Resource
  • Dr. Jean-Marc Hagai Pharm.D.
    Chief Commercial Officer

PYPD Stock Analysis - Frequently Asked Questions

Should I buy or sell PolyPid stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for PolyPid in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PYPD shares.
View PYPD analyst ratings
or view top-rated stocks.

How have PYPD shares performed in 2024?

PolyPid's stock was trading at $3.80 on January 1st, 2024. Since then, PYPD shares have increased by 21.1% and is now trading at $4.60.
View the best growth stocks for 2024 here
.

When is PolyPid's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our PYPD earnings forecast
.

How were PolyPid's earnings last quarter?

PolyPid Ltd. (NASDAQ:PYPD) issued its earnings results on Wednesday, February, 14th. The company reported ($3.97) earnings per share for the quarter, missing analysts' consensus estimates of ($2.17) by $1.80.

When did PolyPid's stock split?

PolyPid's stock reverse split before market open on Thursday, September 21st 2023. The 1-30 reverse split was announced on Wednesday, September 20th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, September 20th 2023. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of PolyPid own?

Based on aggregate information from My MarketBeat watchlists, some companies that other PolyPid investors own include Advanced Micro Devices (AMD), Moderna (MRNA), Sorrento Therapeutics (SRNE), Trevena (TRVN), Cardinal Health (CAH), Genocea Biosciences (GNCA), LightPath Technologies (LPTH), Stride (LRN) and Livongo Health (LVGO).

When did PolyPid IPO?

PolyPid (PYPD) raised $50 million in an initial public offering (IPO) on Friday, June 26th 2020. The company issued 3,100,000 shares at a price of $15.00-$17.00 per share. Barclays and BMO Capital Markets acted as the underwriters for the IPO and Raymond James, National Securities Corporation, Oddo BHF and A.G.P. were co-managers.

Who are PolyPid's major shareholders?

PolyPid's stock is owned by many different institutional and retail investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of PolyPid?

Shares of PYPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PYPD) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners